Alan Armstrong bought Gilead Sciences Inc (NASDAQ: GILD)
Alan Armstrong (R-OK), a U.S. Senator, has disclosed 1 trade in Gilead Sciences Inc (GILD) since 2026, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Alan Armstrong bought $1,001 - $15,000 of Gilead Sciences Inc (NASDAQ: GILD) on March 27, 2026. Since that trade, GILD is down -2.21% against the S&P 500 up +16.97%, an outperformance of -19.18%.
Data updated
Alan Armstrong's GILD trades vs the price
GILD is down -2.21% since Alan Armstrong bought on March 27, 2026, versus +16.97% for the S&P 500.
Performance since this trade
All Alan Armstrong GILD trades
Alan Armstrong & GILD trading FAQ
Is it legal for Alan Armstrong to trade Gilead Sciences Inc (GILD) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Gilead Sciences Inc (GILD), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Alan Armstrong buy GILD?
Alan Armstrong disclosed a purchase of $1,001 - $15,000 of Gilead Sciences Inc (GILD) on March 27, 2026, according to public STOCK Act filings.
How has GILD performed since Alan Armstrong's trade?
Since Alan Armstrong bought GILD on March 27, 2026, the stock is down -2.21%, versus +16.97% for the S&P 500 over the same period, an outperformance of -19.18%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional GILD trades?
Quantellect tracks every disclosed congressional trade in Gilead Sciences Inc (GILD) on the Gilead Sciences Inc congressional trading page, which aggregates filings across all members of Congress.
Alan Armstrong's GILD tradesAll congressional filings for Gilead Sciences IncAlan Armstrong's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.